InterWest Management Partners IX, LLC's Net Worth

$371 Million

Estimate Recalculated Feb 16, 2024 04:30PM EST

Who is InterWest Management Partners IX, LLC?

InterWest Management Partners IX, LLC has an estimated net worth of $371 Million. This is based on reported shares across multiple companies, which include EnteroMedics Inc, Trius Therapeutics Inc, GLAUKOS Corp, Carbylan Therapeutics, Inc., Marketo, Inc., Venus Concept Inc., and Transcept Pharmaceuticals Inc.

SEC CIK

InterWest Management Partners IX, LLC's CIK is 0001398927

Past Insider Trading and Trends

2014 was InterWest Management Partners IX, LLC's most active year for acquiring shares with 32 total transactions. InterWest Management Partners IX, LLC's most active month to acquire stocks was the month of April. 2014 was InterWest Management Partners IX, LLC's most active year for disposing of shares, totalling 27 transactions. InterWest Management Partners IX, LLC's most active month to dispose stocks was the month of April. 2010 saw InterWest Management Partners IX, LLC paying a total of $9,397,557.48 for 3,548,643 shares, this is the most they've acquired in one year. In 2013 InterWest Management Partners IX, LLC cashed out on 11,830,626 shares for a total of $70,818,664.12, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Trius Therapeutics Inc No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
3.55M
$4.77
3.55M
Aug 6
Form 3
0
0
No matching records found

GLAUKOS Corp (GKOS) Snapshot price: $94.4

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
2.6M
2.6M
Jun 30
Form 3
0
0
No matching records found

Carbylan Therapeutics, Inc. (KALV) Snapshot price: $14.54

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
4.62M
$5.00
4.62M
Apr 14
Form 3
0
0
No matching records found

Marketo, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-71.64%
-124.48K
$24.31
-$3,006,776.01
49.27K
May 29 - May 30
Form 4
-17.35%
-848.00K
4.04M
May 28
Form 4
-39.07%
-10.00K
$24.01
-$240,090.00
15.6K
May 20 - May 21
Form 4
-36.95%
-15.00K
$22.96
-$344,427.00
25.6K
May 16
Form 4
-100.00%
-34.46K
$24.27
-$836,427.15
0
May 13 - May 14
Form 4
-14.63%
-848.00K
4.95M
May 12
Form 4
-61.95%
-24.42K
$41.96
-$1,024,605.20
15K
Feb 27 - Feb 28
Form 4
-61.55%
-33.05K
$40.33
-$1,334,791.50
20.65K
Feb 26
Form 4
-18.79%
-1.35M
5.85M
Feb 25
Form 4
-100.00%
-4.35K
$40.70
-$177,045.00
0
Feb 13
Form 4
-5.89%
-451.49K
7.21M
Feb 12
Form 4
-21.37%
-2.08M
$33.99
-$70,818,664.12
7.66M
Sep 18
Form 4
9.75M
9.75M
May 22
Form 3
0
0
No matching records found

Venus Concept Inc. (VERO) Snapshot price: $1.33

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+84.47%
301.61K
658.66K
Nov 7
Form 4
0
0
Aug 20
Form 4
+59.60%
2M
$1.50
$3,000,000.00
5.36M
Aug 9
Form 4
3.36M
$7.00
3.36M
Oct 16
Form 4
0
0
Oct 11
Form 3
0
0
No matching records found